EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Characterization of Serum Phosphate Levels Over Time with Intravenous Ferric Carboxymaltose Versus Placebo as Treatment for Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Exploratory Prospective Substudy From HEART-FID

Nina Nouhravesh, Jyotsna Garg, Frank W Rockhold, Carmine G De Pasquale, Eileen O'Meara, Gregory D Lewis, Javed Butler, Josephine Harrington, Justin A Ezekowitz, Piotr Ponikowski, Richard W Troughton, Yee Weng Wong und 5 weitere

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3348 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Nina Nouhravesh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, NC, USA. Hauptthemen laut MEDLINE: Ferric Compounds, Maltose, Heart Failure, Phosphates. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NHLBI NIH HHS, American Regent, American Regent, a Daiichi Sankyo Group company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Ferric carboxymaltose (FCM) is guideline-recommended for iron deficiency (ID) in heart failure with reduced ejection fraction (HFrEF). Despite a well-established safety profile, the magnitude and clinical significance of FCM-induced hypophosphataemia in HFrEF remains unclear. This pre-specified substudy of HEART-FID evaluated serum phosphate, 1,25-dihydroxyvitamin D, and plasma parathyroid hormone (PTH) subsequent to FCM. Methods and results HEART-FID was a randomized, double-blind, placebo-controlled trial of ambulatory patients with HFrEF and ID randomized to FCM versus placebo. This substudy assessed mean change from baseline across eight visits over 6 months for the following endpoints: serum phosphate, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and PTH, in addition to the clinical severity of potential hypophosphataemia. Overall, 133 patients (n = 62 FCM, n = 71 placebo) were prospectively enrolled. Mean age was 68 ± 11 years, 55 (41.4%) were women, and 29 (21.8%) had chronic kidney disease. Phosphate levels decreased in 34 (57.6%) patients in the FCM group compared with 7 (10.3%) in the placebo group. Mean change in phosphate levels reached a nadir at day 21 (−0.36 ± 0.27 mmol/L) subsequent to FCM infusion with 28 (51%) having moderate-to-severe hypophosphataemia. Reductions in 1,25-dihydroxyvitamin D were also observed, whilst PTH increased. These biochemical changes returned to baseline levels by day 91. Serum levels of 25-hydroxyvitamin D remained stable throughout the study. No serious adverse events associated with hypophosphataemia were reported.

Conclusions

Transient moderate-to-severe hypophosphataemia was frequent subsequent to FCM infusion, accompanied by 1,25-dihydroxyvitamin D decrease and PTH increase. Serum levels of 25-hydroxyvitamin D remained stable. No evidence of symptomatic hypophosphataemia was reported, collectively indicating FCM-related hypophosphataemia to be clinically benign and transient in HFrEF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ferric CompoundsMaltoseHeart FailurePhosphatesStroke VolumeAnemia, Iron-DeficiencyHypophosphatemiaHumansFemaleMaleDouble-Blind MethodAgedProspective StudiesMiddle AgedVitamin DTreatment OutcomeParathyroid HormoneIron Deficiencies

Stichwörter der Autor:innen

Ferric carboxymaltoseHeart failure with reduced ejection fractionHypophosphataemia

Substanzen

ferric carboxymaltoseFerric CompoundsMaltosePhosphatesVitamin DParathyroid Hormone1,25-dihydroxyvitamin D25-hydroxyvitamin D

Autor:innen und Institutionen

  • Duke Clinical Research Institute, Durham, NC, USA.
  • Department of Cardiology, Herlev-Gentofte University Hospital, Copenhagen, Denmark.
  • Flinders Medical Centre, Adelaide, SA, Australia.
  • Montreal Heart Institute and Université de Montréal, Quebec, Canada.
  • Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA.
  • Department of Medicine, University of Mississippi, Jackson, MS, USA.

Förderung

  • NHLBI NIH HHS
  • American Regent
  • American Regent, a Daiichi Sankyo Group company

Zitieren

APA

Nouhravesh, N., Garg, J., Rockhold, F. W., De Pasquale, C. G., O'Meara, E., Lewis, G. D., Butler, J., Harrington, J., Ezekowitz, J. A., Ponikowski, P., Troughton, R. W., Wong, Y. W., Blackman, N., Numan, S., Adamczyk, R., Hernandez, A. F., & Mentz, R. J. (2025). Characterization of Serum Phosphate Levels Over Time with Intravenous Ferric Carboxymaltose Versus Placebo as Treatment for Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Exploratory Prospective Substudy From HEART-FID. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3348

Vancouver

Nouhravesh N, Garg J, Rockhold FW, De Pasquale CG, O'Meara E, Lewis GD, et al. Characterization of Serum Phosphate Levels Over Time with Intravenous Ferric Carboxymaltose Versus Placebo as Treatment for Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Exploratory Prospective Substudy From HEART-FID. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3348

BibTeX
@article{Nouhravesh2025,
  author = {Nouhravesh, Nina and Garg, Jyotsna and Rockhold, Frank W and De Pasquale, Carmine G and O'Meara, Eileen and Lewis, Gregory D and Butler, Javed and Harrington, Josephine and Ezekowitz, Justin A and Ponikowski, Piotr and Troughton, Richard W and Wong, Yee Weng and Blackman, Nicole and Numan, Syed and Adamczyk, Robert and Hernandez, Adrian F and Mentz, Robert J},
  title = {Characterization of Serum Phosphate Levels Over Time with Intravenous Ferric Carboxymaltose Versus Placebo as Treatment for Heart Failure with Reduced Ejection Fraction and Iron Deficiency: An Exploratory Prospective Substudy From HEART-FID},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3348}
}
Kostenlos starten →